Article
Identification of pharmacogenetic biomarkers for efficacy of cytoreductive surgery plus hyperthermic intraperitoneal mitomycin C in patients with colorectal peritoneal metastases.
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology - 1 Oct 2020
Hulshof E C, Lurvink R J, Caserta N, de Hingh I H J T, van Wezel T, Böhringer S, Swen J J, Gelderblom H, Guchelaar H J, Deenen M J
Abstract excerpt
INTRODUCTION: Mitomycin C (MMC) is commonly used in patients with colorectal peritoneal metastases (CPM) treated with cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (CRS + HIPEC). MMC requires metabolic activation prior to exert its cytotoxic effect of which the main activating enzymes are NQO1 and POR. However, not all patients are able to activate MMC for example due to polymorphisms in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.